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The inflammatory response requires the adhesion of multiple
leukocyte types with other leukocytes, extracellular matrices
and with other cell types. Leukocytes must adhere to vascular
endothelial cells and to extraceilular matrices in order to
migrate from peripheral circulation to sites of inflammation. T
lymphocytes must adhere to class Il-positive antigen presenting
cells in order to initiate a cascade of events that leads to T cell
activation, allowing the T cell to provide help in both the
generation of the antibody response and the generation of
cytotoxic T cells (CTL). Also effector leukocytes such as NK
cells, CTL or granulocytes must adhere to appropriate target
cells such as virally infected cells, tumor cells or cells from
transplanted allogeneic organs. This adherence both stimulates
the leukocyte to perform lytic functions and allows local
concentrations of lytic mediators secreted from the effector
leukocyte to accumulate at the leukocyte/target cell junction.
Several families of adhesion molecules have been identified
over the past 10 years which facilitate some or all aspects of
leukocyte adhesion, This article will concentrate on the CD18
family of leukocyte adhesion molecules interacting with one of
their ligands, intercellular adhesion molecule-l (ICAM-l).
Other adhesion molecules will be discussed elsewhere in this
issue.
The CD18 family of adhesion molecules belong to the integrin
supergene family and specifically are the only members of the
beta2 family. They consist of three heterodimers having a
unique alpha subunit noncovalently associated with a common
beta subunit. While the distribution of the individual het-
erodimers vary, no member is expressed on non-hemopoietic
cells, and the vast majority of leukocytes express at least one of
the three heterodimers. In general, LFA-l (CD11aJCDI8) is
expressed on all leukocytes while Mac-l and P150,95 (CDI1b/
CD18 and CD11c/CD18, respectively) are expressed on most
leukocytes of the myeloid lineage as well as subpopulations of
NK cells and B cells 11—31.
The function of the CD18 family of adhesion molecules as
well as their role in mediating an inflammatory response became
evident by two lines of research. The first line was the devel-
opment of monoclonal antibodies (MAb) against individual
subunits of these molecules which were able to antagonize their
function and thus prevent leukocyte adhesion to endothelial
cells and target cells, Furthermore, these antibodies inhibited in
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vitro models of inflammation such as the mixed lymphocyte
response (MLR) and assays of cell mediated cytolysis [1—3, 4].
Concurrent with the elucidation of the structure and function of
the CDI8 family of adhesion molecules was the identification of
a small group which, due to genetic aberrations of the gene
encoding the common beta subunit, were unable to express any
member of the CD18 family on their leukocyte surface. Leuko-
cytes from these patients were unable to adhere normally to
cellular substrates and behaved comparably to normal leuko-
cytes in the presence of anti-CD18 MAID. Furthermore, these
leukocyte adhesion deficient (LAD) patients were unable to
mount normal inflammatory responses, They presented with
delayed umbilical cord separation, had frequent skin infections
with little or no leukocyte infiltrate and the severely deficient
patients (expressing less than 1% of the normal number of CD18
molecules on their leukocyte surface) had defective T and B cell
responses [5, 6]. These LAD patients taught us that the CDI8
family of adhesion molecules were important for leukocyte
adhesion and that without these molecules, the inflammatory
response would be greatly impaired. Furthermore, they showed
that the role of CD18 was solely to mediate inflammation since
the LAD patients had no other apparent phenotypic aberrations
in terms of development or health other than a defective
defense system. This suggested that a specific inhibitor of CD18
would be a successful means of attenuating an inflammatory
response without creating severe side effects other than the
desired immunosuppression.
A ligand for at least two members of the CD18 family of
adhesion molecules (LFA-i and Mac-i) is ICAM-i [7, 8].
Unlike CD18, however, ICAM-l is found on a variety of cell
types. It is inducible with inflammatory cytokines such as IL-i,
TNFa and/or IFN-y depending on the cell type [9—li]. In situ a
low basal expression of ICAM-l has been found on vascular
endothelial cells, and increased expression has been seen on
endothelial cells, keratinocytes, melanomas, hepatocytes,
mesangial cells, astrocytes, lymphocytes and macrophages at
sites of inflammation [12—17]. Structurally, ICAM-l is a mem-
ber of the immunoglobulin supergene family, having five immu-
noglobulin-like domains, a transmembrane region and a cyto-
plasmic tail. Binding to LFA-I has been mapped to domain 1 of
ICAM-l [3].
Antibodies directed against ICAM-l inhibit many of the same
assays in vitro as antibodies to CDI8 or a CDII molecule.
These include leukocyte adhesion to endothelium [18], mixed
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lymphocyte responses [19] and antigen-induced proliferation
assays [201.
Given the choice to develop a MAb as a potential anti-
inflammatory therapeutic, we chose an anti-ICAM-1 over an
anti-CD 18 because ICAM-1 was expressed mostly at the sites of
inflammation, thus with very little constitutive expression an
antibody to ICAM-1 would target to a site of inflammation, such
as rejection or ischemia following reperfusion. To this end we
identified a mouse anti-human ICAM-1 that cross reacts with
rabbit, and nonhuman primate ICAM-1 that could be used in
various in vivo models of inflammation to assess its therapeutic
potential as an anti-inflammatory agent. Three of these models
will now be described.
One of the earliest models we used to look at the in vivo
activity of anti-ICAM-1 was a rabbit inflammatory lung model
[211. In this model, a chemotactic stimuli was given i.v., and 18
to 24 hours later the lungs were lavaged and the number of cells
in the bronchoalveolar lavage fluid (BAL) were quantitated.
While control animals given no antibody or irrelevant MAb had
a large number of polymorphonuclear cells in the BAL, animals
treated with anti-ICAM-l prior to the stimuli had only a small
increase in the number of cells in the BAL, suggesting, at least
in terms of neutrophils, that anti-ICAM-l behaved in vivo as it
did in vitro. This encouraged us to look at anti-ICAM-1 in other
models involving either granulocyte and/or lymphocyte medi-
ated inflammation.
One model of inflammation we looked at was an antigen-
induced airway hyperreactivity model in cynomologus mon-
keys [22]. In this model, animals that had been selected for their
sensitivity to Ascaris antigen were given three doses of inhaled
Ascaris antigen on days 1, 3, and 5 of the protocol. Three days
after the final antigen administration, the amount of inhaled
methacholine necessary to induce bronchoconstriction was
measured, as well as quantitating the number and types of cells
in the BAL. The less methacholine needed to induce broncho-
constriction, the more airway hyperreactivity was available.
This feature is reminiscent of asthma in humans. Invariably
multiple inhaled challenges increased airway hyperreactivity.
However when anti-ICAM-l was given daily from day 0 to 7 of
the protocol, both eosinophil influx into the airway and airway
hyperreactivity were greatly reduced, suggesting that anti-
ICAM-1 inhibited either eosinophil trafficking into the lungs
and/or effector functions mediated by eosinophils.
Another model where anti-ICAM-1 was tested is of particular
interest. This was a model of allogeneic kidney transplant in
cynomologus monkeys established by Cosimi Ct al [17]. In this
model monkeys were given daily doses of anti-ICAM-l MAb
for 12 days starting two days prior to transplantation. After
transplantation the monkeys were monitored for urine output
and serum creatinine levels as signs of rejection. When it was
clear that rejection was occurring, the experiment was ended
and the days of graft survival were considered the end point. It
should be stressed that there were no other immunosuppres-
sives used in this protocol. The results of these experiments
revealed that animals not given MAb had graft survival aver-
aging 9,2 0.6 days while anti-ICAM-l treated animals had
graft survival averaging 24.2 2,4 days. This showed that
anti-ICAM-1, at least while it was present in the circulation,
was immunosuppressive in terms of preventing rejection.
In another protocol, cynomologus monkeys were given ta-
pering doses of cyclosporin A (CsA) after an allogeneic kidney
transplant until subtherapeutic levels of CsA were achieved, as
indicated by a rise in serum creatinine. At this point, while
maintaining the subtherapeutic levels of CsA, anti-ICAM-1 was
administered daily for 10 days. Again allograft survival was
monitored. Whereas control animals' kidneys survived 8 to 14
days after the initial observation of a rise in serum creatinine, all
anti-ICAM-1 treated animals showed a reversal in the creatinine
spike. Furthermore, some allografts survived up to 55 days
post-spike. What was of interest was that biopsies of treated
animals revealed a heavy mononuclear cell infiltrate in the
absence of apparent rejection. This suggested that anti-ICAM-l
inhibited cytotoxic T cell activity in the graft. Whether the
mononuclear cells seen at the time of biopsy were those cells
that had migrated to the graft prior to the onset of anti-ICAM- I
therapy or freshly recruited cells is not known. In any case,
these data suggest that there is an anti-inflammatory effect of
anti-ICAM-l in immunological rejection.
In summary, anti-ICAM-1 has been shown to attenuate
inflammatory models mediated by granulocytes and lympho-
cytes, and suggests that ICAM-l antagonists may provide an
effective means of attenuating inflammation.
Reprint requests to Robert Rot h/em, Boehringer Ingeiheim Pharma-
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